Osteoporosis Drugs Market Expected to Reach $10 Billion by 2026

According to a new report published by Allied Market Research, titled, "Osteoporosis Drugs Market by Drug Class, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019–2026," the global osteoporosis drugs market size was valued at $8 billion in 2018, and is expected to reach $10 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026.

Osteoporosis is a medical condition which involves the weakening of the bones. This medical condition is caused due to the overexpression of the parathyroid hormone. Moreover, the weak bones are porous and susceptible to serious fractures. Therefore, osteoporosis has a significant impact on quality of life of patients such as the condition leads to limited mobility. Thus, this medical condition requires treatment which includes the administration of drugs such as bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors and others. Furthermore, these drugs are administered through different routes in the body. For instance, some osteoporosis drugs are administered through the oral route whereas others are administered through the intravenous route. 

The major factor that contributes toward the growth of global osteoporosis drugs market include rise in prevalence of osteoporosis. Furthermore, other factors that boost osteoporosis drugs market growth include surge in geriatric population across the globe and rise in adoption of sedentary lifestyle worldwide. However, side effects of osteoporosis drugs, and the time-consuming drug approval process restrain the growth of the global osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.

The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. By drug class, it is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Depending on route of administration, it is fragmented into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

By drug class, the bisphosphonates segment acquired the major share of osteoporosis drugs market in 2018 owing to increase in investment in R&D of advanced novel bisphosphonates drugs by major players.  However, rank ligand inhibitors segment is expected to exhibit fastest growth rate during the forecast period owing to the fact that these drugs are used treat bone metastasis by acting as a chemoattractant to bone for tumor cells that express its receptor, RANK. Thus, the inhibition of the RANKL-RANK pathway acts as an ideal treatment for bone metastasis which makes them a preferred choice of drug.

By route of administration, the oral segment acquired for the major share of the osteoporosis drugs market owing to large number of osteoporosis medications which are available as oral drugs in the market. However, the injectable segment is expected to grow at the fastest CAGR during the forecast period owing to factors such as rise in need for drugs which exhibit enhanced bioavailability, and act rapidly.

By region, North America accounted for the major osteoporosis drugs market share in 2018 and is expected to continue this trend, owing to easy availability of osteoporosis drugs. Moreover, surge in the incidence of osteoporosis is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. Moreover, the constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia.

Key Findings of the Study:

• Bisphosphonates occupied more than one-third share of the global osteoporosis drugs market in 2018.
• The RANK ligand inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
• The oral segment in drug class accounted for more than more than half the share of the market in 2018.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA